Case Report: CD19 and CD22 CAR-T therapy induced durable complete remission in a patient with refractory plasmablastic lymphoma

IntroductionPlasmablastic lymphoma (PBL) is a rare and highly aggressive form of non-Hodgkin lymphoma that is associated with a poor prognosis. Traditional chemotherapy has demonstrated limited efficacy for PBL. There is currently no standard treatment for patients with refractory or relapsing PBL....

Full description

Bibliographic Details

Published in:	Frontiers in Immunology
Main Authors:	Dan Liu, Haichen Wei, Yanran Hu, Hui Wang, Ping Li, Ke Lu, Wenjun Zhang, Lijie Xing, Zengjun Li
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-10-01
Subjects:	plasmablastic lymphoma refractory car-t bortezomib daratumumab
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1697566/full